Study #2024-0028
A phase 1b, multicenter, open-label study of Valemetostat Tosylate in combination with DXd ADCs in subjects with solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
Valemetostat tosylate, T-DXd, Dato-DXd
Description
This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Phase I
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-563-0193
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.